Waltham, MA – According to filings with the U.S. Securities and Exchange Commission, OncXerna Therapeutics is raising $100,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Laura Benjamin played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About OncXerna Therapeutics
Existing precision medicines target just 10 percent of cancers those with gene mutations or oncogenic drivers for a small number of genes. OncXerna Therapeutics is ushering in a new era of precision medicine, leveraging the company’s deep understanding of tumor biology at the RNA level to deliver more effective therapies for many more patients. OncXerna applies its understanding of RNA signatures to describe the dominant biology of the patients cancer and match it to therapies with mechanisms that modify the dominant biology to dramatically improve patient outcomes.

To learn more about OncXerna Therapeutics, visit http://oncxerna.com/

Contact:
Laura Benjamin, Chief Executive Officer
781-907-7810
https://www.linkedin.com/in/laura-e-benjamin-04299b34/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved